Table 1. Coalition for Epidemic Preparedness Innovations Vaccine-Development Partnerships up to March 2019.
| Company | Development a | Date of Partnership Announcement |
|---|---|---|
| Themis Bioscience | $37.5 million to develop a vaccine against Lassa virus and MERS-CoV, using a measles vector technology | March 2018 |
| Inovio | $56 million to develop a DNA vaccine against Lassa virus and MERS-CoV | April 2018 |
| IAVI | $54.9 million to develop a vaccine against Lassa virus, using a replication-competent vesicular stomatitis virus vector technology | May 2018 |
| Profectus Biosciences, Emergent, and PATH | $25 million to develop a recombinant subunit protein vaccine against Nipah virus | May 2018 |
| Profectus Biosciences, Emergent, and PATH | $36 million to develop an attenuated VesiculoVax vaccine against Lassa virus | June 2018 |
| IDT Biologika | $36 million to develop a vaccine against MERS-CoV virus, using a recombinant, modified vaccinia Ankara vector technology | August 2018 |
| Janssen and University of Oxford | $19 million to develop a vaccine against Lassa virus, MERS-CoV, and Nipah virus, using a simian adenoviral vaccine vector technolog | September 2018 |
| Imperial College | $8.4 million to develop a self-amplifying RNA vaccine platform that enables tailored vaccine production against multiple viral pathogens (including H1N1 influenza, rabies virus, and Marburg virus) | December 2019 |
| University of Queensland | $10.6 million to develop a “molecular clamp” vaccine platform, a transformative technology that enables targeted and rapid vaccine production against multiple viral pathogens (including influenza virus, MERS-CoV, and respiratory syncytial virus) | December 2019 |
| University of Tokyo | $31 million to develop a vaccine against Nipah virus by inserting the Nipah-virus G gene (Malaysia strain) into a measles vector (Edmonston B strain) | February 2019 |
| CureVac | $34 million to develop The RNA Printer prototype, a transportable, down-scaled, automated mRNA printing facility, that can produce rapidly a supply of lipid-nanoparticle–formulated mRNA vaccine candidate that can target known pathogens (including Lassa fever, yellow fever, and rabies); and prepare for rapid response to unknown pathogens (i.e., Disease X) | February 2019 |
| Themis Bioscience | $21 million to advance a vaccine against chikungunya virus through phase 3 clinical trials and to accelerate its regulatory approval so at-risk populations have access to the vaccine, using a measles vector technology | June 2019 |
| Wageningen Bioveterinary Research | $12.5 million for vaccine manufacturing, preclinical research, and a phase 1 study to assess the safety, tolerability, and immunogenicity of a single-dose vaccine candidate against Rift Valley fever, using an attenuated virus technology | July 2019 |
| Colorado State University | $9.5 million for manufacturing and preclinical studies to assess a single-dose vaccine candidate against Rift Valley fever, using an attenuated virus technology | July 2019 |
| Valneva | $23.4 million for vaccine manufacturing and late-stage clinical development of a single-dose, live-attenuated vaccine against chikungunya virus | July 2019 |
| Public Health Vaccines | $43.6 million to advance the development and manufacture of a vaccine against the Nipah virus, using a recombinant vesicular stomatitis virus technology | August 2019 |
Abbreviations: MERS-CoV, Middle East respiratory syndrome coronavirus; mRNA, messenger RNA.
a Cited funding is reported in US dollars.